{"id":390783,"date":"2017-12-15T00:00:00","date_gmt":"2017-12-15T00:00:00","guid":{"rendered":"https:\/\/clarivate.com\/life-sciences-healthcare\/report\/acreim0019-2017-biopharma-ulcerative-colitis-crohns-disease-access-and-reimbursement-us\/"},"modified":"2026-03-31T10:49:11","modified_gmt":"2026-03-31T10:49:11","slug":"acreim0019-2017-biopharma-ulcerative-colitis-crohns-disease-access-and-reimbursement-us","status":"publish","type":"report","link":"https:\/\/clarivate.com\/life-sciences-healthcare\/report\/acreim0019-2017-biopharma-ulcerative-colitis-crohns-disease-access-and-reimbursement-us\/","title":{"rendered":"Ulcerative Colitis &#038; Crohn&#8217;s Disease | Access and Reimbursement | US"},"content":{"rendered":"<p><strong>MARKET OUTLOOK<\/strong><\/p>\n<p>The <abbr title=\"United States\">U.S.<\/abbr> ulcerative colitis (<abbr title=\"ulcerative colitis\">UC<\/abbr>) and Crohn\u2019s disease (<abbr title=\"Crohn's disease\">CD<\/abbr>) markets include the predominantly entrenched <abbr title=\"tumor necrosis factor\">TNF<\/abbr>-\u03b1 inhibitors (e.g., Janssen\/Merck\u2019s Remicade, AbbVie\/Eisai\u2019s Humira). However, recent entries that offer alternative treatment options for <abbr title=\"tumor necrosis factor\">TNF<\/abbr>-\u03b1 refractory patients (i.e., Takeda\u2019s Entyvio and Janssen\u2019s Stelara), as well as the arrival of biosimilar infliximab (Pfizer\u2019s Inflectra), continue to evolve the <abbr title=\"ulcerative colitis\">UC<\/abbr>\/<abbr title=\"Crohn's disease\">CD<\/abbr> treatment landscapes. The potential arrival of several more agents offering novel <abbr title=\"mechanism of action\">MOA<\/abbr>s and\/or formulations (e.g., Pfizer\u2019s tofacitinib, Gilead\/Galapagos\u2019 filgotinib, Roche\/Genentech\u2019s etrolizumab), as well as increasing physician experience with prescribing biosimilars, will fuel competition and pricing pressure in these markets. Emerging therapies looking to gain favorable uptake in <abbr title=\"ulcerative colitis\">UC<\/abbr> and\/or <abbr title=\"Crohn's disease\">CD<\/abbr> will face a growing number of challenges to impress physicians and payers alike, and may struggle to gain robust uptake and\/or favorable formulary placement.<\/p>\n<p><strong>QUESTIONS ANSWERED<\/strong><\/p>\n<ul>\n<li><strong>What is the current and expected formulary placement of key biological agents prescribed for <abbr title=\"ulcerative colitis\">UC<\/abbr> and <abbr title=\"Crohn's disease\">CD<\/abbr>, and how are utilization management strategies employed by <abbr title=\"managed care organization\">MCO<\/abbr>s to control costs of these agents?<\/strong><\/li>\n<li><strong>How do <abbr title=\"managed care organization\">MCO<\/abbr> restrictions impact physicians\u2019 prescribing of biologics to their <abbr title=\"ulcerative colitis\">UC<\/abbr> or <abbr title=\"Crohn's disease\">CD<\/abbr> patients?<\/strong><\/li>\n<li><strong>How do payers expect to cover emerging therapies (e.g., Pfizer\u2019s tofacitinib, Gilead\/Galapagos\u2019 filgotinib, Roche\/Genentech\u2019s etrolizumab) on their commercial health plans at various price points and how does this align with physicians\u2019 anticipated prescribing of these therapies?<\/strong><\/li>\n<li><strong>What impact will biosimilar entries have on payer coverage of the originator brands and what impact will biosimilars have on physicians\u2019 prescribing decisions?<\/strong><\/li>\n<\/ul>\n<p><strong>PRODUCT DESCRIPTION<\/strong><\/p>\n<p>Access &#038; Reimbursement: Provides in-depth insight regarding the impact of payer policy on physician prescribing behavior so you can build your market access strategy and optimize your brand positioning.<\/p>\n","protected":false},"template":"","class_list":["post-390783","report","type-report","status-publish","hentry","report-gateway-biopharma","biopharma-therapy-areas-crohns-disease","biopharma-therapy-areas-ulcerative-colitis","biopharma-geography-us","biopharma-date-890"],"acf":[],"publishpress_future_workflow_manual_trigger":{"enabledWorkflows":[]},"_links":{"self":[{"href":"https:\/\/clarivate.com\/life-sciences-healthcare\/wp-json\/wp\/v2\/report\/390783","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/clarivate.com\/life-sciences-healthcare\/wp-json\/wp\/v2\/report"}],"about":[{"href":"https:\/\/clarivate.com\/life-sciences-healthcare\/wp-json\/wp\/v2\/types\/report"}],"version-history":[{"count":2,"href":"https:\/\/clarivate.com\/life-sciences-healthcare\/wp-json\/wp\/v2\/report\/390783\/revisions"}],"predecessor-version":[{"id":576767,"href":"https:\/\/clarivate.com\/life-sciences-healthcare\/wp-json\/wp\/v2\/report\/390783\/revisions\/576767"}],"wp:attachment":[{"href":"https:\/\/clarivate.com\/life-sciences-healthcare\/wp-json\/wp\/v2\/media?parent=390783"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}